on DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies presents at the Goldman Sachs Global Healthcare Conference
DBV Technologies, a specialist in food allergy treatment options, announced that its CEO, Daniel Tassé, will participate in the 47th annual Global Healthcare Conference hosted by Goldman Sachs. The event will be held in Miami, Florida, on June 9, 2026. Tassé will participate in an informal discussion, which will be streamed live on DBV's website and available for replay for 90 days.
DBV is known for its VIASKIN® technology, used in epicutaneous immunotherapy to treat food allergies. Based in France with operations in the United States, the company is listed on Euronext Paris and Nasdaq.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DBV TECHNOLOGIES news